Refine by
Cancer Tissue Articles & Analysis
64 news found
This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative diseases. For example, Multiple Sites of Normal Brain Tissue Microarray, 80 Cases, 26 Cores (Catalog NO. ...
This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug discovery, cancer research, and tissue engineering. The Centre of Excellence will house state-of-the-art CELLINK bioprinters, including the flagship BIO X6 and BIONOVA X bioprinters, a range of bioinks and the leading ...
ByCELLINK
” Now hospitals can use the technology while we learn more about the long term (>10 years) outcomes of using the NanoKnife System for prostate cancer as they collect their audit data. When men are diagnosed with prostate cancer it is graded as Low, Intermediate or High risk. ...
IVS’s functional 3D tissue models reconstitute the physiological properties of human cardiac, smooth and skeletal muscle as well as connective tissues that support cancer growth. ...
Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. ...
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed ...
SKOUT, a real-time computer-aided polyp detection device with FDA 510(k) clearance, uses advanced computer vision technology designed to recognize suspicious tissue during colorectal cancer screening and surveillance. SKOUT significantly improves overall adenoma detection compared to standard colonoscopy. ...
xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer. As the knowledge of cancer and ...
ByxCures
(“FutureChem”) (KOSDAQ: 220100ks), a leading Korean radiopharmaceutical company developing innovative medicines and imaging analysis technology for targeting and treating cancer and neurodegenerative diseases. Under the agreement, both companies will conduct collaborative research utilizing antibody assets discovered from PharmAbcine’s proprietary fully human ...
“X-ZELL’s single-cell technology could genuinely change the way we think about cancer diagnostics as it will make powerful new data available from non-invasive sources – in a format that is scalable and fit for the digital ...
National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). ...
Patients with incurable breast cancer could potentially benefit from new Welsh-led research, latest evidence suggests. ...
The Company’s fourth proprietary platform has the potential to expand further its pipeline of novel anti-cancer mAbs and the versatility to yield other drug formats including antibody drug conjugate and CAR-T candidates. ...
ByScancell
Grote also co-authored X-ZELL’s breakthrough study on the accuracy of tumour-associated circulating endothelial cells as a screening biomarker for clinically significant prostate cancer, which was published in Cancers in late 2019. During his time helming the Marketing & Strategy department, X-ZELL won the coveted MedTech Innovator APAC competition as ...
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. ...
(Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022. ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer ...
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast ...
Leblond, in collaboration with Kevin Petrecca, director of the brain tumour research program and chief of neurosurgery at the Montreal Neurological Institute-Hospital, developed a hand-held probe using Raman spectroscopy to distinguish cancer from healthy tissue. Currently, CT and MRI imaging are used to examine tumours, but they do not show tumours to their ...
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence. ...